# Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05101096/  
OnCo record `nct05101096` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Sacituzumab govitecan in triple-negative breast cancer and bladder & urothelial cancer, run by Gilead Sciences, active and no longer recruiting.

## Summary

Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05101096 by Gilead Sciences, with 135 participants enrolled, started 2021-10-20 and due to reach its primary completion in 2027-05. Interventions recorded: Sacituzumab Govitecan-hziy.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05101096
- Phase: 1/2
- Setting: A Phase 1/2 Open-Label Study of Sacituzumab Govitecan in Japanese Patients With Advanced Solid Tumors (ASCENT-J02)
- Sponsor: Gilead Sciences
- Enrolled: 135

## Sources

- ClinicalTrials.gov NCT05101096: https://clinicaltrials.gov/study/NCT05101096

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct05101096.json